Who are Experimental : Ezetimibe / Rosuvastatin + Telmisartan's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/experimental-ezetimibe-rosuvastatin-telmisartan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Experimental : Ezetimibe / Rosuvastatin + Telmisartan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Experimental : Ezetimibe / Rosuvastatin + Telmisartan (Experimental : Ezetimibe / Rosuvastatin + Telmisartan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination: Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor + Angiotensin II receptor ant

phase 3 Combination: Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor + Angiotensin II receptor antagonist Niemann-Pick C1-like 1 (NPC1L1), HMG-CoA reductase, Angiotensin II type 1 receptor (AT1R) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Experimental : Ezetimibe / Rosuvastatin + Telmisartan (Experimental : Ezetimibe / Rosuvastatin + Telmisartan) — Hanlim Pharm. Co., Ltd.. This combination reduces cholesterol and blood pressure by inhibiting intestinal cholesterol absorption and HMG-CoA reductase while blocking angiotensin II receptors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Experimental : Ezetimibe / Rosuvastatin + Telmisartan TARGET	Experimental : Ezetimibe / Rosuvastatin + Telmisartan	Hanlim Pharm. Co., Ltd.	phase 3	Combination: Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor + Angiotensin II receptor antagonist	Niemann-Pick C1-like 1 (NPC1L1), HMG-CoA reductase, Angiotensin II type 1 receptor (AT1R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination: Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor + Angiotensin II receptor antagonist class)

Hanlim Pharm. Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Experimental : Ezetimibe / Rosuvastatin + Telmisartan — Competitive Intelligence Brief. https://druglandscape.com/ci/experimental-ezetimibe-rosuvastatin-telmisartan. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab